Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and Vietnam (WEIGHT DIVERSE)

April 7, 2026 updated by: Novo Nordisk A/S

Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Cross-sectional Study in India, Pakistan, Philippines and Vietnam

This study is investigating how common weight related health problems are in people of different weight categories in India, Pakistan, Philippines, and Vietnam. The purpose of the study is to understand the prevalence of weight related health problems in different weight groups. Participants will continue their normal care and will not get any treatment as part of this study; participants will continue receiving any treatments their doctor has prescribed. The study will last for about 2 years.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1170

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • India
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110029
        • AIIMS,Delhi
  • Pakistan
      • Lahore, Pakistan, 54810
        • National Hospital Lahore
  • Philippines
    • San Juan
      • Metro Manila, San Juan, Philippines, 1502
        • Asian Hospital and Medical Center
  • Vietnam
    • Tan Binh
      • Ho Chi Minh City, Tan Binh, Vietnam, 700000
        • Tam Anh TP. Ho Chi Minh General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Participants will be assessed for obesity-related complications, including measurement of Body Mass Index (BMI)

Description

Inclusion Criteria:

  • Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
  • Male or female aged 18 years or older at the time of signing informed consent.
  • Presence of at least one Weight-related complication.

Exclusion Criteria:

  • Participants less than 18 years of age at the time of signing informed consent.
  • Pregnant women and individuals with recent weight loss due to illness, defined as more than 5 percent (%) weight loss in the past 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cohort 1
Participants will be assessed for obesity-related complications, including measurement of Body Mass Index (BMI)
Other: No treatment given
No treatment given

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Weight-Related Complications Across Different Body Mass Index (BMI) Classes
Time Frame: Upon data collection (Day 1)
Percentage (%)
Upon data collection (Day 1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novo Nordisk A/S

Investigators

  • Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 18, 2025

Primary Completion (Actual)

October 11, 2025

Study Completion (Actual)

October 11, 2025

Study Registration Dates

First Submitted

February 20, 2025

First Submitted That Met QC Criteria

February 20, 2025

First Posted (Actual)

February 25, 2025

Study Record Updates

Last Update Posted (Actual)

April 8, 2026

Last Update Submitted That Met QC Criteria

April 7, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DAS-8265
  • U1111-1308-4250 (Other Identifier: World Health Organization (WHO))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on No treatment given

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe